highly significantp < 0.001
The difference in PFS distribution between the 2 groups was highly significant (p < 0.001) (Fig. 3 ). 17 patients were reported to have experienced SAEs (4.9%) and 83 patients to have experienced AEs during the administration of trastuzumab.